Barbara Kienzle, BSN, RN
Augusta University’s Children’s Hospital of Georgia
This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.
Learning Objectives and Goals
Upon completion of this activity, participants should be able to:
- Analyze opportunities to optimize therapy in patients with PsA based on medication efficacy and side effect profile
- Assess learners’ ability to empathize with PsA patients about common issues related to their day-to-day struggles
- Identify appropriate questions to ask PsA patients at each visit that may help quickly uncover core issues to be resolved by the patient and healthcare team
Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).
Participants will receive 0.5 hours of continuing nursing contact hours, including .5 pharmacotherapeutic hours, by completing the education, completing an online evaluation, and receiving a post-test score of 70%.
According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational
materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE, Promotional event talks; H, Honoraria; O, Other.
Disclosures are as follows
Barbara Kienzle, BSN, RN, has disclosed the following relevant financial relationships specific to the subject matter of the content of the activity: Mallinckrodt/A.
Off-Label Product Disclosure
This activity will include a discussion of the following off-label or investigational product use:
Risankizumab, bimenkizumab, dimethyl fumerate, and piclidenoson (CF101).
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 75% or greater), and program evaluation. Your certificate can be printed immediately.
This activity is supported by educational grants from Pfizer and AbbVie.
This course will expire on 4/2/2023